Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | BRD4 | O60885 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | MB | P02144 | 1/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.64 |
| ▸ | CA3 | P07451 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13986883 | 0.92 | CACNA1B (0.76) | ALDH1A1TP53SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL11507112 | 0.88 | MAPT (0.70) | ALDH1A1TP53SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL18406003 | 0.88 | MAPT (0.71) | ALDH1A1TP53SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL861674 | 0.87 | SMN1; SMN2 (0.84) | ALDH1A1SMN1; SMN2L3MBTL1HTTMAPT | |
| SCHEMBL13696926 | 0.87 | ALDH1A1 (0.57) | ALDH1A1TP53SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL3633396 | 0.86 | NPC1 (0.84) | ALDH1A1TP53SMN1; SMN2HTTMAPT | |
| SCHEMBL29623006 | 0.86 | SMN1; SMN2 (0.67) | ALDH1A1TP53SMN1; SMN2L3MBTL1HTT | |
| SCHEMBL6459176 | 0.84 | NPC1 (0.69) | ALDH1A1TP53SMN1; SMN2HTTMAPT | |
| SCHEMBL13210697 | 0.84 | CACNA1B (0.85) | ALDH1A1TP53SMN1; SMN2L3MBTL1HTT | |
| Acedoben SCHEMBL24320 | 0.84 | ALDH1A1 (0.68) | ALDH1A1TP53SMN1; SMN2L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112795017-A | Preparation method of silicone rubber with polar functional groups | 张爱民 | 2021-05-14 | — | — | CN | claimed |
| US-8815940-B2 | Coumarin-chalcones as anticancer agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-26 | — | — | US | claimed |
| US-20130210909-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-08-15 | — | — | US | claimed |
| EP-2601183-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | Council Of Scientific & Industrial Research (IN) | 2013-06-12 | — | — | EP | claimed |
| WO-2012017454-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-02-09 | — | — | WO | claimed |
| JP-61246156-A | — | — | None | — | — | JP | disclosed |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2024-11-07 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-4218557-A | PROTECTIVE COATINGS, MOLDINGS, FOAMS | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1980-08-19 | — | — | US | disclosed |
| US-4216313-A | Antiviral thiazinyl benzimidazoles | ELI LILLY AND COMPANY (US) | 1980-08-05 | — | — | US | disclosed |
| EP-0010231-A1 | Polyphosphazene polymers containing N-substituted amido and imido substituents and process for their preparation | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1980-04-30 | — | — | EP | disclosed |
| US-4174454-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1979-11-13 | — | — | US | disclosed |
| US-4150028-A | Antiviral thiazolinyl benzimidazoles | ELI LILLY AND COMPANY (US) | 1979-04-17 | — | — | US | disclosed |
| US-4118742-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4065500-A | Water-soluble quaternary ammonium azo dyestuffs | STERLING DRUG INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-4057530-A | STABILIZERS FOR VINYL CHLORIDE POLYMERS | LABAZ (FR) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | ALDH1A1 295/4885TP53 3874/4885SMN1; SMN2 3760/4885 |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | ALDH1A1 2512/4885TP53 3873/4885SMN1; SMN2 2765/4885 |
| US-20130210909-A1 | COUMARIN-CHALCONES AS ANTICANCER AGENTS | HCCS, XPO5, CIAPIN1 | ALDH1A1 1241/4885TP53 43/4885SMN1; SMN2 4661/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | ALDH1A1 2512/4885TP53 3873/4885SMN1; SMN2 2765/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | ALDH1A1 2512/4885TP53 3873/4885SMN1; SMN2 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.